INDIANAPOLIS, IN – Pharmaceutical giant Eli Lilly announced the availability of its new obesity treatment, Zepbound, in U.S. pharmacies. The drug, priced at $550 monthly for uninsured patients, is half its list price, targeting a significant share in the burgeoning weight-loss drug market.
Zepbound enters a market projected to reach approximately $100 billion by the decade’s end. Wall Street analysts anticipate Zepbound’s sales to hit around $2 billion by 2024, competing closely with Novo Nordisk’s Wegovy, another obesity medication expected to reach sales of about $7.5 billion.
Both Zepbound and Wegovy belong to the GLP-1 agonist class, initially developed for type 2 diabetes management. These drugs have demonstrated effectiveness in reducing food cravings and slowing stomach emptying, contributing to weight loss.
